Drug reference

Ciclosporin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1250

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Ciclosporin inhibits production and release of lymphokines, thereby suppressing cell-mediated immune response.

PDF page 1250

Indications And Dose

IKERVIS ® Severe keratitis in dry eye disease that has not responded to treatment with tear substitutes (initiated by a specialist) ▶TO THE EYE ▶Adult: Apply 1 drop once daily, to be applied to the affected eye(s) at bedtime, review treatment at least every 6 months

PDF page 1250

Contra Indications

Active or suspected ocular or peri- ocular infection. Ocular or peri-ocular malignancies or premalignant conditions

PDF page 1250

Cautions

Glaucoma—limited information available. history of ocular herpes—no information available

PDF page 1250

National Funding Access Decisions

NICE decisions ▶Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (December 2015) NICE TA369 Ciclosporin (Ikervis ®) is recommended as an option, within its marketing authorisation, for treating severe keratitis in patients with dry eye disease that has not improved despite treatment with tear substitutes. www.nice.org.uk/guidance/ta369

PDF page 1250

Safety

Interactions

→Appendix 1: ciclosporin

PDF page 1250

Side Effects

▶Common or very common Eye discomfort. eye disorders. eye inﬂammation. vision blurred ▶Uncommon Eye deposit. increased risk of infection

PDF page 1250

Pregnancy

Manufacturer advises avoid unless potential beneﬁt outweighs risk—no information available.

PDF page 1250

Breast Feeding

Manufacturer advises avoid—limited information.

PDF page 1250

Dose and formulations

Directions For Administration

Manufacturer advises keep eyes closed for 2 minutes after using eye drops to increase local drug action and reduce systemic absorption.

PDF page 1250

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Eye drops ▶Ikervis (Santen UK Ltd) Ciclosporin 1 mg per 1 ml Ikervis 0.1% eye drops 0.3ml unit dose | 30 unit dose P £72.00 DT = £72.00 NERVE GROWTH FACTORS

PDF page 1250

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of blurred vision.

PDF page 1250

Dose text by age group

Adult

Apply 1 drop once daily, to be applied to the

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1250

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Ciclosporin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1250

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Ciclosporin inhibits production and release of lymphokines, thereby suppressing cell-mediated immune response.

PDF page 1250

Indications And Dose

PDF page 1250

Contra Indications

Active or suspected ocular or peri- ocular infection. Ocular or peri-ocular malignancies or premalignant conditions

PDF page 1250

Cautions

Glaucoma—limited information available. history of ocular herpes—no information available

PDF page 1250

National Funding Access Decisions

PDF page 1250

Safety

Interactions

→Appendix 1: ciclosporin

PDF page 1250

Side Effects

▶Common or very common Eye discomfort. eye disorders. eye inﬂammation. vision blurred ▶Uncommon Eye deposit. increased risk of infection

PDF page 1250

Pregnancy

Manufacturer advises avoid unless potential beneﬁt outweighs risk—no information available.

PDF page 1250

Breast Feeding

Manufacturer advises avoid—limited information.

PDF page 1250

Dose and formulations

Directions For Administration

Manufacturer advises keep eyes closed for 2 minutes after using eye drops to increase local drug action and reduce systemic absorption.

PDF page 1250

Medicinal Forms

PDF page 1250

Clinical care

Patient And Carer Advice

Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of blurred vision.

PDF page 1250

Dose text by age group

Adult

Apply 1 drop once daily, to be applied to the

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1250

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.